Therefore, we conducted this systematic review and meta-analysis to evaluate the clinical efficacy and safety of ADC monotherapy in patients with advanced or metastatic HER2-positive GC, with a focus on the ORR and overall safety profile. Here, ERBB2 is linked to gastric cancer.